- Trial phase
- Approved
- Time to market
- Already marketed since 2013. The key commercial change is the expected loss of exclusivity in December 2026, allowing generic competition.
- Why 3/10
- TRINTELLIX is already approved and marketed with no pending FDA regulatory decision or pivotal readout. The approaching loss of exclusivity in December 2026 is a known, planned-for event, not a binary catalyst. For Takeda, a large diversified pharmaceutical company, this is one of many products, limiting the share-price impact of this single drug's generic erosion.
No upcoming regulatory decision or clinical readout is scheduled for TRINTELLIX; the next material event is the expected arrival of generic vortioxetine in pharmacies around December 2026, which the market and Takeda have already anticipated. For Takeda investors, watch the company's broader pipeline (e.g., newer launches replacing TRINTELLIX revenue) and debt reduction progress rather than this single product.
Price Chart
Executive Summary
TRINTELLIX (vortioxetine) is an FDA-approved antidepressant for major depressive disorder (MDD) in adults, first approved in 2013 and marketed in the US by Takeda Pharmaceutical (NYSE: TAK) under a modified collaboration with H. Lundbeck A/S. The drug generates around JPY 121.8 billion (~$800M) in annual revenue for Takeda. The defining event for this product is the expiration of certain exclusivity protections in December 2026, about two months away, which will open the door to generic competition. Takeda has already disclosed this expectation in its annual report and has begun restructuring its US neuroscience sales force accordingly (cutting 243 roles in January 2026). For Takeda, a large diversified pharma company, TRINTELLIX is one of many products and the loss of exclusivity is a known, planned-for event rather than a surprise binary catalyst.
How It Works
TRINTELLIX is a once-daily oral antidepressant that works by affecting several serotonin receptors in the brain (a "multimodal" mechanism), distinguishing it from traditional SSRIs. It is used to treat major depressive disorder (MDD) in adults.
Trial Status
TRINTELLIX has been FDA-approved for MDD in adults since 2013. Pediatric studies in adolescents and children have been conducted but the drug is not approved for pediatric use. The drug is fully commercialized, with no active pivotal trials for new indications being tracked in public sources.
The Two-Sided Case
Upcoming Catalysts
- Loss of exclusivity and expected generic entry for TRINTELLIX in December 2026 (approximately two months from now)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
TAKEDA PHARMACEUTICAL CO LTD 6-K TAK ·Originating report